Inhibition of HIV-1 Tat activity correlates with down-regulation of bcl-2 and results in reduction of angiogenesis and oncogenicity

Virology. 2002 Jul 20;299(1):1-7. doi: 10.1006/viro.2002.1459.

Abstract

The Tat protein of the human immunodeficiency virus type 1 promotes survival and growth and inhibits apoptosis of different cell types. These effects of Tat are attributed to the induction of bcl-2 gene expression. In this study we show that the blocking of both intracellular and extracellular Tat correlates with a decrease of bcl-2 transcripts, leading in vitro to a lower growth rate and attenuation of the transformed phenotype and in vivo to a reduced angiogenic and oncogenic activity of Tat-expressing cells. These results support the notion that bcl-2 is an effector of Tat-induced angiogenesis and oncogenesis and indicate that the blocking of Tat functions by immunoprophylactic, pharmacological, and gene therapy approaches may help to control oncogenesis during AIDS.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / pharmacology
  • Antisense Elements (Genetics)
  • Apoptosis
  • Carcinogenicity Tests
  • Distamycins / pharmacology
  • Down-Regulation
  • Gene Expression Regulation, Viral / drug effects
  • Gene Products, tat / antagonists & inhibitors
  • Gene Products, tat / genetics
  • Gene Products, tat / physiology*
  • HIV-1*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mice, Transgenic
  • Neovascularization, Pathologic*
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • RNA, Messenger / analysis
  • Tumor Cells, Cultured
  • tat Gene Products, Human Immunodeficiency Virus

Substances

  • Antibodies
  • Antisense Elements (Genetics)
  • Distamycins
  • Gene Products, tat
  • PNU 153429
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Messenger
  • tat Gene Products, Human Immunodeficiency Virus